[go: up one dir, main page]

CR20220325A - Fluoroalquil-oxadiazoles y sus usos - Google Patents

Fluoroalquil-oxadiazoles y sus usos

Info

Publication number
CR20220325A
CR20220325A CR20220325A CR20220325A CR20220325A CR 20220325 A CR20220325 A CR 20220325A CR 20220325 A CR20220325 A CR 20220325A CR 20220325 A CR20220325 A CR 20220325A CR 20220325 A CR20220325 A CR 20220325A
Authority
CR
Costa Rica
Prior art keywords
fluoroalkyl
oxadiazole
disorders
inhibitors
various diseases
Prior art date
Application number
CR20220325A
Other languages
English (en)
Inventor
David Sperandio
John Lee
Martin Holan
Alok Nerurkar
Ulhas Bhatt
Frederick Seidl
Julio Medina
Snahel Patel
Tien Widjaja
Pingyu Ding
Yihong Li
Mohammad A Mandegar
Original Assignee
Tenaya Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tenaya Therapeutics Inc filed Critical Tenaya Therapeutics Inc
Publication of CR20220325A publication Critical patent/CR20220325A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<pre> </pre> En la presente descripción se proporcionan compuestos identificados como inhibidores de la actividad de HDAC6 que pueden usarse para tratar diversas enfermedades y transtornos.
CR20220325A 2019-12-20 2020-12-21 Fluoroalquil-oxadiazoles y sus usos CR20220325A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962951853P 2019-12-20 2019-12-20
US202063027602P 2020-05-20 2020-05-20
US202063064516P 2020-08-12 2020-08-12
PCT/US2020/066439 WO2021127643A1 (en) 2019-12-20 2020-12-21 Fluoroalkyl-oxadiazoles and uses thereof

Publications (1)

Publication Number Publication Date
CR20220325A true CR20220325A (es) 2022-08-19

Family

ID=76478049

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220325A CR20220325A (es) 2019-12-20 2020-12-21 Fluoroalquil-oxadiazoles y sus usos

Country Status (15)

Country Link
US (3) US11578066B1 (es)
EP (1) EP4076448A4 (es)
JP (1) JP2023508907A (es)
KR (1) KR20220119653A (es)
CN (1) CN114980887A (es)
AU (1) AU2020407664A1 (es)
BR (1) BR112022011917A2 (es)
CA (1) CA3165424A1 (es)
CO (1) CO2022009438A2 (es)
CR (1) CR20220325A (es)
EC (1) ECSP22051247A (es)
IL (1) IL294052A (es)
MX (1) MX2022007376A (es)
PH (1) PH12022551475A1 (es)
WO (1) WO2021127643A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
KR102316234B1 (ko) * 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
IL294052A (en) 2019-12-20 2022-08-01 Tenaya Therapeutics Inc Fluoroalkyl-oxadiazoles and uses thereof
KR102537615B1 (ko) * 2020-02-25 2023-05-30 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
KR20240013098A (ko) 2021-04-23 2024-01-30 테나야 테라퓨틱스, 인코포레이티드 확장성 심근병증의 치료에 사용하기 위한 hdac6 억제제
EP4333841A1 (en) * 2021-05-04 2024-03-13 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
CN117980294A (zh) * 2021-09-01 2024-05-03 海南先声再明医药股份有限公司 泛素特异性蛋白酶1（usp1）抑制剂
TW202412772A (zh) * 2022-07-19 2024-04-01 義大利商義大利藥品股份有限公司 作為選擇性組蛋白去乙醯酶６抑制劑之１，３，４－㗁二唑衍生物
CN119677723A (zh) 2022-08-08 2025-03-21 意大发马克股份公司 作为选择性hdac6抑制剂的二氟和三氟乙酰基酰肼
TW202430521A (zh) * 2022-10-14 2024-08-01 美商特納亞治療股份有限公司 用於改善病毒生產之化合物
WO2024079682A1 (en) * 2022-10-14 2024-04-18 Chong Kun Dang Pharmaceutical Corp. Sulfoximine compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3187611B2 (ja) 1993-05-17 2001-07-11 キヤノン株式会社 液晶性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法および表示装置
JP2000511883A (ja) 1996-04-19 2000-09-12 ノボ ノルディスク アクティーゼルスカブ ホスホチロシン認識ユニットを有する分子のモジュレーター
EP0826685A1 (en) 1996-08-21 1998-03-04 Pfizer Inc. Stable, long acting salts of carboxamides for the treatment of joint disease
DE19744792A1 (de) 1997-10-10 1999-04-15 Hoechst Ag Triptycenderivate und ihre Verwendung für optoelektronische Anwendungen, insbesondere als Elektrolumineszenzmaterialien
CA2269050A1 (en) 1998-04-14 1999-10-14 Shigeo Yanai Method for transdermal administration of gp iib/iiia antagonist
CA2346396C (en) 1998-10-09 2009-04-28 Janssen Pharmaceutica N.V. 4,5-dihydro-isoxazole derivatives and their pharmaceutical use
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
WO2003074038A1 (en) 2002-02-28 2003-09-12 Icagen, Inc. Methods for treating diseases related to intraocular pressure
US7119112B2 (en) 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
BRPI0407306A (pt) 2003-02-07 2006-02-21 Janssen Pharmaceutica Nv 1,2,4- triazinas de inibição de hiv
KR20110132482A (ko) 2003-02-07 2011-12-07 얀센 파마슈티카 엔.브이. Ｈｉｖ 감염 예방용 피리미딘 유도체
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
US7169797B2 (en) 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
JP2007223901A (ja) 2004-03-24 2007-09-06 Takeda Chem Ind Ltd 複素環化合物およびその用途
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
EP1824812A4 (en) 2004-11-23 2009-10-28 Merck & Co Inc AGONISTS OF THE NIACIN RECEPTOR, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT PROCEDURES
US8889742B2 (en) 2004-11-30 2014-11-18 The Trustees Of The University Of Pennsylvania Use of HDAC and/or DNMT inhibitors for treatment of ischemic injury
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
JP2008303145A (ja) 2005-09-22 2008-12-18 Takeda Chem Ind Ltd Ｇｒｋ阻害剤からなる強心薬
DE102005049385A1 (de) 2005-10-15 2007-04-19 Sanofi-Aventis Deutschland Gmbh Imidazolderivate als Inhibitoren von TAFIa
US7863414B2 (en) 2005-11-18 2011-01-04 The Board Of Regents Of The University Of Texas Systems Methods of treatment and uses for CaMKII and its interaction with HDACs and calpain
US20070207950A1 (en) 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
US8492378B2 (en) 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
US20080207704A1 (en) 2007-02-27 2008-08-28 The Green Cross Corporation Heteroaryl-imidazole derivatives as cannabinoid cb1 receptor antagonists
WO2008140708A1 (en) 2007-05-09 2008-11-20 The Trustees Of The University Of Pennsylvania Use of hdac inhibitors for treatment of cardiac rhythm disorders
JP2009017059A (ja) * 2007-07-02 2009-01-22 Canon Inc 画像処理装置及び画像処理方法
UA105000C2 (uk) * 2008-02-20 2014-04-10 Новартіс Аг ГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ СТЕАРОЇЛ-СоА-ДЕСАТУРАЗИ
SI2291080T1 (sl) 2008-05-14 2015-11-30 The Scripps Research Institute Novi modulatorji sfingosinskih fosfatnih receptorjev
CA2727078A1 (en) 2008-06-23 2009-12-30 Basf Se Sulfoximinamide compounds for combating animal pests
US8637505B2 (en) 2009-02-04 2014-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
BRPI1007923A2 (pt) 2009-02-06 2020-08-25 Elan Pharmaceuticals, Inc composto, composição farmacêutica, métodos para tratar uma doença neurodegenerativa, e para reduzir a concentração de p-cjun em tecido cerebral de um indivíduo em necessidade do mesmo, uso de um composto, e, método in vitro
MX2011011127A (es) 2009-04-24 2011-11-18 Glaxo Group Ltd 3-azabiciclo[4.1.0] heptanos usados como antagonistas de orexina.
JP2011008205A (ja) 2009-05-27 2011-01-13 Fujifilm Corp 二軸性光学異方性膜を作製するための組成物
US8883827B2 (en) 2009-06-05 2014-11-11 Oslo University Hospital Hf Azole derivatives as WTN pathway inhibitors
CN103492391A (zh) 2009-09-25 2014-01-01 沃泰克斯药物股份有限公司 用于制备用作蛋白激酶抑制剂的嘧啶衍生物的方法
WO2011132048A1 (en) 2010-04-19 2011-10-27 Glenmark Pharmaceutical S.A. Heteroaryl compounds as pde10a inhibitors
RU2012154447A (ru) 2010-05-12 2014-06-20 Вандербилт Юниверсити Гетероциклические сульфоновые аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций
WO2012018499A2 (en) 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
EP2625171B1 (en) 2010-10-07 2014-07-30 Basf Se Phenanthro[9,10-b]furans for electronic applications
WO2012054510A1 (en) 2010-10-19 2012-04-26 Comentis, Inc. Oxadiazole compounds which inhibit beta-secretase activity and methods of use thereof
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
CA2820800A1 (en) 2010-12-08 2012-06-14 Oslo University Hospital Hf Triazole derivatives as wnt signaling pathway inhibitors
US9181214B2 (en) 2011-06-09 2015-11-10 Rhizen Pharmaceuticals Sa Bicyclic compounds as modulators of GPR-119
WO2013066835A2 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
WO2014047662A2 (en) 2012-09-24 2014-03-27 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
WO2014179144A1 (en) 2013-04-29 2014-11-06 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
CN105377849B (zh) 2013-06-17 2018-01-26 巴斯夫欧洲公司 用于防除动物害虫的取代嘧啶*化合物和衍生物
CN105873577B (zh) 2013-08-30 2019-06-18 西奈山伊坎医学院 环插烯酰胺作为溴结构域抑制剂
EP3066077A4 (en) 2013-11-05 2017-08-09 C & C Biopharma, LLC Treatment of cardiac remodeling and other heart conditions
CN103613693B (zh) 2013-11-29 2015-10-07 中科院广州化学有限公司 两亲性含氟纳米微球/含氟环氧树脂杂化体的制法及应用
EP2946788A1 (en) 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
EP3152195A4 (en) 2014-06-04 2017-12-13 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of cancer
CA2951912A1 (en) 2014-06-12 2015-12-17 University Of Notre Dame Du Lac Composition and method for the treatment of neurological diseases and cerebral injury
EP3157917B1 (en) 2014-06-19 2020-03-18 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
WO2016004318A1 (en) 2014-07-02 2016-01-07 Shire Human Genetic Therapies, Inc. Encapsulation of messenger rna
PT3204378T (pt) 2014-10-08 2019-11-12 Redx Pharma Plc Derivados de n-oiridinil acetamida como inibidores da trajetória de sinalização de wnt
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
GB201507340D0 (en) 2015-04-29 2015-06-10 Univ St Andrews Light emitting devices and compounds
EP3328844B1 (en) 2015-07-27 2019-11-27 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole sulfamide derivatives as histone deacetylase 6 inhibitor and pharmaceutical composition comprising the same
CA2993929C (en) 2015-07-27 2020-10-20 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
TWI694075B (zh) * 2015-08-04 2020-05-21 韓商鐘根堂股份有限公司 作為組蛋白去乙醯酶６抑制劑之１,３,４-㗁二唑衍生物及含彼之醫藥組合物
GB201514015D0 (en) 2015-08-07 2015-09-23 Arnér Elias S J And Dept Of Health And Human Services Novel pyridazinones and their use in the treatment of cancer
GB201514756D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
JP2018532772A (ja) 2015-09-16 2018-11-08 メタクリン，インク． ファルネソイドｘ受容体アゴニストおよびそれらの使用
DK3350165T3 (da) 2015-09-16 2023-09-25 Organovo Inc Farnesoid-X-receptoragonister og anvendelser deraf
US10696642B2 (en) 2015-09-23 2020-06-30 The General Hospital Corporation TEAD transcription factor autopalmitoylation inhibitors
NZ740809A (en) * 2015-10-12 2019-04-26 Chong Kun Dang Pharmaceutical Corp Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2017075192A1 (en) 2015-10-27 2017-05-04 Acetylon Pharmaceuticals, Inc. Hdac inhibitors for the treatment of diabetic peripheral neuropathy
TW201808914A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
WO2017222951A1 (en) * 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2017222950A1 (en) * 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-heterocyclyl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2018029602A1 (en) 2016-08-08 2018-02-15 Hetero Labs Limited C-3 novel triterpenone with c-28 heterocycle derivatives as hiv inhibitors
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
ES2885243T3 (es) 2017-06-01 2021-12-13 Bristol Myers Squibb Co Compuestos que contienen nitrógeno sustituido
CA3071825A1 (en) * 2017-07-31 2019-02-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
BR112020006256A2 (pt) 2017-09-29 2020-10-20 Intellia Therapeutics, Inc. método in vitro de administração de mrna usando nanopartículas de lipídio
US20190216751A1 (en) 2017-11-15 2019-07-18 California State University Northridge Compositions and Methods for the Treatment and Prevention of Cancer
CN111587249A (zh) * 2017-11-20 2020-08-25 阿里根公司 吲哚化合物及其用途
AU2018380132B2 (en) 2017-12-06 2023-11-09 Lin Bioscience, Inc. Tubulin inhibitors
EP3724188B1 (en) 2017-12-12 2023-06-07 Arkuda Therapeutics Progranulin modulators and methods of using the same
US20210009541A1 (en) * 2018-02-12 2021-01-14 Bayer Aktiengesellschaft Fungicidal oxadiazoles
WO2019171234A1 (en) 2018-03-09 2019-09-12 Pi Industries Ltd. Heterocyclic compounds as fungicides
WO2019173790A1 (en) 2018-03-09 2019-09-12 Timothy Hla Pyridinone- and pyridazinone-based compounds and medical uses thereof
KR20210016344A (ko) 2018-05-04 2021-02-15 인플라좀 리미티드 신규한 화합물
KR20210056953A (ko) 2018-05-30 2021-05-20 트랜슬레이트 바이오 인코포레이티드 전령 rna 백신 및 이의 용도
US11572362B2 (en) 2018-08-13 2023-02-07 Gilead Sciences, Inc. Pyrrolo[1,2-b]pyridazine derivatives
WO2020097511A2 (en) 2018-11-09 2020-05-14 Translate Bio, Inc. Messenger rna therapy for treatment of ocular diseases
EP3953360B1 (en) 2019-04-09 2024-02-28 F. Hoffmann-La Roche AG Heterocyclic compounds as inhibitors of monoacylglycerol lipase (magl)
CA3140170A1 (en) 2019-06-04 2020-12-10 Belew Mekonnen Imidazolo derivatives, compositions and methods as orexin antagonists
CA3140173A1 (en) 2019-06-04 2020-12-10 Belew Mekonnen Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
WO2021048242A1 (en) 2019-09-12 2021-03-18 F. Hoffmann-La Roche Ag 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
PL4031547T3 (pl) 2019-09-18 2024-10-07 Takeda Pharmaceutical Company Limited Inhibitory kalikreiny osoczowej i ich zastosowania
WO2021067859A1 (en) 2019-10-03 2021-04-08 Tenaya Therapeutics, Inc. 5-fluoronicotinamide derivatives and uses thereof
CA3155979A1 (en) 2019-10-23 2021-04-29 Case Western Reserve University Method of modulating ribonucleotide reductase
US20230000959A1 (en) 2019-12-02 2023-01-05 The Regents Of The University Of Colorado, A Body Corporate Histone Deacytlase 6 Modulation of Titin Protein Mediated Cardiac Tissue Stiffness and Method for Same
IL294052A (en) 2019-12-20 2022-08-01 Tenaya Therapeutics Inc Fluoroalkyl-oxadiazoles and uses thereof
WO2021183796A1 (en) 2020-03-12 2021-09-16 3+2 Pharma Cbp/catenin signaling pathway inhibitors and uses thereof
AU2021239135B2 (en) 2020-03-16 2024-05-02 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Substituted pyrimidine or pyridine amine derivative, composition thereof, and medical use thereof
BR112022026083A2 (pt) 2020-06-26 2023-01-17 Nihon Nohyaku Co Ltd Derivado de ariltetra-hidropiridazina ou sal do mesmo, agente inseticida contendo o composto, e método de uso do mesmo
CN115916752A (zh) 2020-06-26 2023-04-04 日本农药株式会社 芳基四氢吡啶衍生物或其盐类、和含有该化合物的杀虫剂及其使用方法
UY39385A (es) 2020-08-18 2022-02-25 Pi Industries Ltd Nuevos compuestos heterocíclicos para combatir los hongos fitopatógenos
FI4129989T3 (fi) 2020-08-26 2024-12-16 Haisco Pharmaceuticals Pte Ltd Dipeptidyylipeptidaasi 1:n estäjänä toimiva nitriilijohdannainen ja sen käyttö
CN112794860B (zh) 2021-03-24 2021-06-29 上海肇钰医药科技有限公司 噁唑嘧啶酮酰胺类化合物或其可药用盐，制备方法及用途
KR20240013098A (ko) 2021-04-23 2024-01-30 테나야 테라퓨틱스, 인코포레이티드 확장성 심근병증의 치료에 사용하기 위한 hdac6 억제제
EP4333841A1 (en) 2021-05-04 2024-03-13 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef

Also Published As

Publication number Publication date
US11578066B1 (en) 2023-02-14
CO2022009438A2 (es) 2022-07-29
CA3165424A1 (en) 2021-06-24
KR20220119653A (ko) 2022-08-30
US20230143804A1 (en) 2023-05-11
BR112022011917A2 (pt) 2022-09-06
EP4076448A1 (en) 2022-10-26
PH12022551475A1 (en) 2023-11-29
WO2021127643A1 (en) 2021-06-24
CN114980887A (zh) 2022-08-30
IL294052A (en) 2022-08-01
EP4076448A4 (en) 2024-03-27
ECSP22051247A (es) 2022-07-29
AU2020407664A1 (en) 2022-08-18
MX2022007376A (es) 2022-09-02
US20240182462A1 (en) 2024-06-06
JP2023508907A (ja) 2023-03-06
US11926622B2 (en) 2024-03-12

Similar Documents

Publication Publication Date Title
CR20220325A (es) Fluoroalquil-oxadiazoles y sus usos
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
MX379543B (es) Purinonas como inhibidores de proteasa específica de ubiquitina 1.
CO2018013077A2 (es) Inhibidores de la arginasa y sus aplicaciones terapéuticas
EA201991556A1 (ru) Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции
EA201790660A1 (ru) Ингибитор киназ
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
MX377273B (es) Ciclopropilamina como inhibidor de la desmetilasa 1 específica de lisinas (lsd1).
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX2023005484A (es) Analogos de carbamoil fenilalaninol y usos de los mismos.
EA201691447A1 (ru) 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера
PH12017501095A1 (en) Piperidine derivatives as hdac1/2 inhibitors
ECSP14030779A (es) Inhibidores del nampt
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
PH12019500751A1 (en) Carbamoyl phenylalaninol compounds and uses thereof
EA201891468A1 (ru) Композиции и способы для снижения экспрессии tau
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
EA201992137A1 (ru) ПИРИМИДОПИРИМИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ Wee-1
EP3606520A4 (en) SHORT CHAIN DEHYDROGENASE ACTIVITY INHIBITORS FOR THE TREATMENT OF CORONARY DISORDERS
CL2022001006A1 (es) Inhibidores de tim-3 y sus usos
DOP2016000120A (es) Nuevos inhibidores de dgat2
EA201792610A1 (ru) Способ лечения неврологического заболевания
MX2022012386A (es) Compuestos inhibidores de metaloenzimas.